VENTOLIN
LOE ApproachingNDAINHALATIONAEROSOL, METEREDPriority Review
Approved
May 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
Priority Review
VENTOLIN by GSK is 2 -adrenergic receptors compared with isoproterenol. Approved for exercise-induced bronchospasm in adult, older. First approved in 1981.
Drug data last refreshed 1h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VENTOLIN is a metered-dose inhaler (MDI) containing a short-acting beta-2 agonist (SABA) for acute relief of bronchospasm in asthma and COPD patients. It is a first-line rescue medication that works by relaxing airway smooth muscle to rapidly restore breathing. The product has been a cornerstone of respiratory therapy since 1981.
LOE Approaching
As LOE approaches, the focus shifts from growth to defense and lifecycle management; expect smaller, efficiency-focused teams managing generic transition.
Mechanism of Action
2 -adrenergic receptors compared with isoproterenol. Although beta 2 -adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta 1 -adrenoceptors are the predominant receptors in the heart, there are also beta 2 -adrenoceptors in the human heart comprising 10% to 50%…
Indications (2)
Worked on VENTOLIN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.